In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
Justine Habault, Jennifer L Franco, Susan Ha...
https://pubmed.ncbi.nlm.nih.gov/39956770/Actively Recruiting
Led by Parabilis Medicines, Inc. · Updated on 2026-10-07
619
Participants Needed
33
Research Sites
21 weeks
Total Duration
Researchers are evaluating FOG-001, a study drug, in participants with locally advanced or metastatic solid tumors, including those with familial adenomatous polyposis FAP. This Phase 12 trial aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of FOG-001, given alone or combined with other anticancer agents, in tumors with Wnt pathway activating mutations or related conditions. FOG-001 is administered either intravenously or subcutaneously in continuous 28-day cycles. It is studied as monotherapy and in combination with drugs such as mFOLFOX-6, Nivolumab, Trifluridinetipiracil, and Bevacizumab. The trial includes dose escalation and dose expansion phases across multiple subgroups, including various solid tumors, colorectal cancer types, hepatocellular carcinoma, desmoid tumors, metastatic prostate cancer, and FAP. Participants will undergo regular assessments including safety monitoring for adverse events, tumor biopsies, imaging evaluations using RECIST criteria, and blood tests to measure drug levels and response markers such as PSA in prostate cancer. The study tracks outcomes like response rates, disease control, progression-free survival, and pharmacokinetic parameters over approximately 10 months. Safety and tolerability are closely observed during dose escalation and expansion periods.
CONDITIONS
FOG-001 in Locally Advanced or Metastatic Solid Tumors
C
Clinical Trial Inquiries
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Parabilis Medicines, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | FOG‑001 investigational regimen (trial) | Standard chemotherapy plus bevacizumab |
|---|---|---|
| What it is | An investigational WNT‑pathway targeting therapy (FOG‑001) given in sequential dose‑escalation and expansion cohorts, sometimes combined with mFOLFOX‑6, Nivolumab, Trifluridine/Tipiracil, or Bevacizumab | Standard systemic treatment for eligible metastatic colorectal cancer involves cytotoxic chemotherapy plus a biologic agent such as bevacizumab |
| Role in trial | Participants receive FOG‑001, with dosing varied across sequential parts | Not used as part of this study; included only for external context |
| Primary use | To evaluate FOG‑001 safety, dose‑limiting toxicities, pharmacokinetics, and preliminary activity across solid tumor types | Used as first‑line systemic therapy to control disease and improve survival in metastatic colorectal cancer |
| How it is given | FOG‑001 administered intravenously or subcutaneously in 28‑day continuous cycles, with or without combination agents per cohort | Chemotherapy (eg, oxaliplatin‑based doublet) plus bevacizumab given per standard prescribing regimens |
| Evidence status | Early‑phase to mid‑phase clinical evaluation; efficacy not yet established | Supported by clinical evidence and guidelines as effective first‑line treatment in metastatic colorectal cancer |
| Important risks | Unknown; safety profile still under assessment | Known risks include chemotherapy‑related toxicities and bevacizumab‑associated vascular risks |
| Key limitations | Non‑randomized, single‑arm design; heterogeneous tumor types and combination regimens limit attribution of effects | Guideline‑based evidence mainly refers to first‑line colorectal cancer; applicability varies with tumor subtype and prior therapy |
| Patient impact | Unknown impact on outcomes; being investigated | Demonstrated survival benefit and disease control in eligible metastatic colorectal cancer patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial assessments to confirm health status and eligibility
Duration - Up to several cycles of 28 days each
Participants receive increasing doses of FOG-001 alone or with other anticancer drugs to evaluate safety, tolerability, and pharmacodynamics.
Regular visits with safety monitoring and biopsies as needed
Duration - Approximately 10 months on average
Participants receive the recommended dose of FOG-001 alone or in combination to further assess antitumor activity and safety.
Periodic visits every 63 days for tumor assessments and regular monitoring
Duration - Up to study completion in August 2027
After treatment, participants are monitored for disease progression, response duration, and survival outcomes.
Scheduled visits for ongoing evaluation of health and outcomes
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
19
Have more questions? Get in touch with our team for quick support
Justine Habault, Jennifer L Franco, Susan Ha...
https://pubmed.ncbi.nlm.nih.gov/39956770/Parabilis Medicines, Inc.
Lead Sponsor